Pamela J. RussellAMFAHMS (died February 2022)[1] was an Australian academic researcher of
immunology,
bladder and
prostate research.[2] Russell was awarded Membership of the
Order of Australia (AM) for her research on prostate and bladder cancer in 2003.[3]
Russell's postdoctoral training was at the
John Curtin School of Medical Research,
Canberra, and then she moved to Sydney to take up a postdoctoral position at The Kolling Institute of Medical Research.[4]
Russell's early work in Immunology on
Systemic Lupus Erythematosus (SLE) showed that the immunosuppressive drug, cyclophosphamide, could be successfully used to treat animals with this disease, leading to its use in patients with SLE. Early work WEHI showed that T cells could kill cancer cells.[9] Further studies of autoimmunity were performed by Russell's group at the
Kolling Institute specifically SLE.[10] but also some related work in
rheumatoid arthritis and in
ankylosing spondylitis and its association with
HLA-B27.[11][12]
Singh P, Joshi S, Russell PJ, Verma N, Wang XC, Khatri A. Molecular chemotherapy and Chemotherapy: A new front against late stage hormone refractory prostate cancer. Clinical Cancer Research. 2011; 17(12): 1–13[21]
Hung TT, Chan J, Russell PJ, Power CA. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS ONE . 2011, 6(5): e19389, 1-8[22]
Tang C, Russell PJ, Martiniello-Wilks R, Rasko J, Khatri A. Concise Review: Nanoparticles and cellular carriers - allies in imaging and therapy?Stem cells. 2010; 28(9):1686-702-702[23]
Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res.2009; 15(7):2323-2234.[24]
Li Y, Song E, Rizvi SMA, Power CA, Beretov J, Raja C, Cozzi PJ, Morgenstern A, Apostolidis C, Allen BJ, Russell PJ. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted a radioimmunoconjugates. Clin Cancer Res. 2009; 15:865-875[25]
^Russell, Pamela J., and Alfred D. Steinberg. "Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: Depressed phagocytosis of opsonized sheep erythrocytes in vitro." Clinical immunology and immunopathology 27, no. 3 (1983): 387-402.
^Cameron, Fiona H., Pamela J. Russell, Joan F. Easter, Denis Wakefield, and Lyn March. "Failure Of klebsiella pneumoniae antibodies to cross‐react with peripheral blood mononuclear cells from patients with ankylosing spondylitis." Arthritis & Rheumatism 30, no. 3 (1987): 300-305.
^Cameron, Fiona H., Pamela J. Russell, John Sullivan, and Andrew F. Geczy. "Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-B27-positive individuals?." Molecular Immunology 20, no. 5 (1983): 563-566.
Pamela J. RussellAMFAHMS (died February 2022)[1] was an Australian academic researcher of
immunology,
bladder and
prostate research.[2] Russell was awarded Membership of the
Order of Australia (AM) for her research on prostate and bladder cancer in 2003.[3]
Russell's postdoctoral training was at the
John Curtin School of Medical Research,
Canberra, and then she moved to Sydney to take up a postdoctoral position at The Kolling Institute of Medical Research.[4]
Russell's early work in Immunology on
Systemic Lupus Erythematosus (SLE) showed that the immunosuppressive drug, cyclophosphamide, could be successfully used to treat animals with this disease, leading to its use in patients with SLE. Early work WEHI showed that T cells could kill cancer cells.[9] Further studies of autoimmunity were performed by Russell's group at the
Kolling Institute specifically SLE.[10] but also some related work in
rheumatoid arthritis and in
ankylosing spondylitis and its association with
HLA-B27.[11][12]
Singh P, Joshi S, Russell PJ, Verma N, Wang XC, Khatri A. Molecular chemotherapy and Chemotherapy: A new front against late stage hormone refractory prostate cancer. Clinical Cancer Research. 2011; 17(12): 1–13[21]
Hung TT, Chan J, Russell PJ, Power CA. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS ONE . 2011, 6(5): e19389, 1-8[22]
Tang C, Russell PJ, Martiniello-Wilks R, Rasko J, Khatri A. Concise Review: Nanoparticles and cellular carriers - allies in imaging and therapy?Stem cells. 2010; 28(9):1686-702-702[23]
Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res.2009; 15(7):2323-2234.[24]
Li Y, Song E, Rizvi SMA, Power CA, Beretov J, Raja C, Cozzi PJ, Morgenstern A, Apostolidis C, Allen BJ, Russell PJ. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted a radioimmunoconjugates. Clin Cancer Res. 2009; 15:865-875[25]
^Russell, Pamela J., and Alfred D. Steinberg. "Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: Depressed phagocytosis of opsonized sheep erythrocytes in vitro." Clinical immunology and immunopathology 27, no. 3 (1983): 387-402.
^Cameron, Fiona H., Pamela J. Russell, Joan F. Easter, Denis Wakefield, and Lyn March. "Failure Of klebsiella pneumoniae antibodies to cross‐react with peripheral blood mononuclear cells from patients with ankylosing spondylitis." Arthritis & Rheumatism 30, no. 3 (1987): 300-305.
^Cameron, Fiona H., Pamela J. Russell, John Sullivan, and Andrew F. Geczy. "Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-B27-positive individuals?." Molecular Immunology 20, no. 5 (1983): 563-566.